Research progress of tumor budding in esophageal cancer

doi:10.3877/cma.j.issn.2095-8773.2021.01.08

Abstract

Abstract:

As a special pathological feature, tumor budding can be observed in the esophagus, stomach, color, rectum, lung and oral cavity, etc. Tumor budding is an independent factor which can reflect the invasiveness and prognosis of the tumor lesion. In recent years, with increasing scholars’ attention and in-depth studies, it has been shown that tumor budding can be used as a prognostic indicator of esophageal cancer, which is helpful to the clinical treatment decision.

Key words: Esophageal cancer, Tumor budding, Prognosis

Yujia Zheng, Donglai Chen, Wenjia Wang, Wei Wang, Yonghua Sang, Yongsheng Zhang, Yongbing Chen. Research progress of tumor budding in esophageal cancer[J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2021, 08(01): 51-55.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxbwkdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-8773.2021.01.08

https://zhxbwkdzzz.cma-cmc.com.cn/EN/Y2021/V08/I01/51

Figures/Tables 2

References 32

1	Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2): 87-108.
2	Koelzer VH, Langer R, Zlobec I, et al. Tumor budding in upper gastrointestinal carcinomas[J]. Front Oncol, 2014, 4: 216.
3	Berg KB, Schaeffer DF. Tumor budding as a standardized parameter in gastrointestinal carcinomas more than just the colon[J]. Mod Pathol, 2018, 31(6): 862-872.
4	Borggreve AS, Kingma BF, Domrachev SA, et al. Surgical treatment of esophageal cancer in the era of multimodality management[J]. Ann N Y Acad Sci, 2018, 1434(1): 192-209.
5	Hucl T. Role of endosonography prior to endoscopic treatment of esophageal cancer[J]. Minerva Chir, 2018, 73(4): 410-416.
6	Kelly RJ. Emerging Multimodality Approaches to Treat Localized Esophageal Cancer[J]. J Natl Compr Canc Netw, 2019, 17(8): 1009-1014.
7	Grigore AD, Jolly MK, Jia D, et al. Tumor Budding: The Name is EMT. Partial EMT[J]. J Clin Med, 2016, 5(5): 51.
8	Niwa Y, Yamada S, Koike M, et al. Epithelial to mesenchymal transition correlates with tumor budding and predicts prognosis in esophageal squamous cell carcinoma[J]. J Surg Oncol, 2014, 110(6): 764-769.
9	Zöller M. Gastrointestinal tumors: metastasis and tetraspanins[J]. Z Gastroenterol, 2006, 44(7): 573-586.
10	Chouat E, Zehani A, Chelly I, et al. Tumor budding is a prognostic factor linked to epithelial mesenchymal transition in pancreatic ductal adenocarcinoma. Study report and literature review[J]. Pancreatology, 2018, 18(1): 79-84.
11	Jensen DH, Dabelsteen E, Specht L, et al. Molecular profiling of tumour budding implicates TGFβ-mediated epithelial-mesenchymal transition as a therapeutic target in oral squamous cell carcinoma[J]. J Pathol, 2015, 236(4): 505-516.
12	Nakagawa Y, Ohira M, Kubo N, et al. Tumor budding and E-cadherin expression are useful predictors of nodal involvement in T1 esophageal squamous cell carcinoma[J]. Anticancer Res, 2013, 33(11): 5023-5029.
13	Jass JR, Barker M, Fraser L, et al. APC mutation and tumour budding in colorectal cancer[J]. J Clin Pathol, 2003, 56(1): 69-73.
14	Brand S, Dambacher J, Beigel F, et al. CXCR4 and CXCL12 are inversely expressed in colorectal cancer cells and modulate cancer cell migration, invasion and MMP-9 activation[J]. Exp Cell Res, 2005, 310(1): 117-130.
15	Lugli A, Kirsch R, Ajioka Y, et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016[J]. Mod Pathol, 2017, 30(9): 1299-1311.
16	Lugli A, Karamitopoulou E, Zlobec I. Tumour budding: a promising parameter in colorectal cancer[J]. Br J Cancer, 2012, 106(11): 1713-1717.
17	Karamitopoulou E, Zlobec I, Kölzer V, et al. Proposal for a 10-high-power-fields scoring method for the assessment of tumor budding in colorectal cancer[J]. Mod Pathol, 2013, 26(2): 295-301.
18	van Wyk HC, Park J, Roxburgh C, et al. The role of tumour budding in predicting survival in patients with primary operable colorectal cancer: a systematic review[J]. Cancer Treat Rev, 2015, 41(2): 151-159.
19	Ueno H, Murphy J, Jass JR, et al. Tumour 'budding' as an index to estimate the potential of aggressiveness in rectal cancer[J]. Histopathology, 2002, 40(2): 127-132.
20	Jesinghaus M, Brühl F, Steiger K, et al. Cellular Dissociation Grading Based on the Parameters Tumor Budding and Cell Nest Size in Pretherapeutic Biopsy Specimens Allows for Prognostic Patient Stratification in Esophageal Squamous Cell Carcinoma Independent From Clinical Staging[J]. Am J Surg Pathol, 2019, 43(5): 618-627.
21	Landau MS, Hastings SM, Foxwell TJ, et al. Tumor budding is associated with an increased risk of lymph node metastasis and poor prognosis in superficial esophageal adenocarcinoma[J]. Mod Pathol, 2014, 27(12): 1578-1589.
22	Jesinghaus M, Boxberg M, Wilhelm D, et al. Post-neoadjuvant cellular dissociation grading based on tumour budding and cell nest size is associated with therapy response and survival in oesophageal squamous cell carcinoma[J]. Br J Cancer, 2019, 121(12): 1050-1057.
23	Fuchinoue K, Nemoto T, Shimada H, et al. Immunohistochemical analysis of tumor budding as predictor of lymph node metastasis from superficial esophageal squamous cell carcinoma[J]. Esophagus, 2020, 17(2): 168-174.
24	Roh MS, Lee JI, Choi PJ. Tumor budding as a useful prognostic marker in esophageal squamous cell carcinoma[J]. Dis Esophagus, 2004, 17(4): 333-337.
25	Koike M, Kodera Y, Itoh Y, et al. Multivariate analysis of the pathologic features of esophageal squamous cell cancer: tumor budding is a significant independent prognostic factor[J]. Ann Surg Oncol, 2008, 15(7): 1977-1982.
26	Miyata H, Yoshioka A, Yamasaki M, et al. Tumor budding in tumor invasive front predicts prognosis and survival of patients with esophageal squamous cell carcinomas receiving neoadjuvant chemotherapy[J]. Cancer, 2009, 115(14): 3324-3334.
27	Brown M, Sillah K, Griffiths EA, et al. Tumour budding and a low host inflammatory response are associated with a poor prognosis in oesophageal and gastro-oesophageal junction cancers[J]. Histopathology, 2010, 56(7): 893-899.
28	Nakanishi Y, Ohara M, Doumen H, et al. Correlation between tumor budding and post-resection prognosis in patients with invasive squamous cell carcinoma of the thoracic esophagus[J]. World J Surg, 2011, 35(2): 349-356.
29	Teramoto H, Koike M, Tanaka C, et al. Tumor budding as a useful prognostic marker in T1-stage squamous cell carcinoma of the esophagus[J]. J Surg Oncol, 2013, 108(1): 42-46.
30	Thies S, Guldener L, Slotta-Huspenina J, et al. Impact of peritumoral and intratumoral budding in esophageal adenocarcinomas[J]. Hum Pathol, 2016, 52: 1-8.
31	Jesinghaus M, Boxberg M, Konukiewitz B, et al. A Novel Grading System Based on Tumor Budding and Cell Nest Size Is a Strong Predictor of Patient Outcome in Esophageal Squamous Cell Carcinoma[J]. Am J Surg Pathol, 2017, 41(8): 1112-1120.
32	Kemi N, Eskuri M, Ikäläinen J, et al. Tumor Budding and Prognosis in Gastric Adenocarcinoma[J]. Am J Surg Pathol, 2019, 43(2): 229-234.

作者，参考文献号，时间	观察方法	病例数	TB低级别（%）	TB高级别（%）	研究结果
Roh等^[24]，2004	HE	56	22（39.3）	34（60.7）	低级别组和高级别组3年生存率分别为72.3%和32.7%
Koike等^[25]，2008	HE	136	54（39.7）	82（60.3）	低级别组的3年和5年生存率分别为92.0%和81.3%，高级别组的3年和5年生存率分别为42.6%和35.4%
Miyata等^[26]，2009	HE	71	42（59）	29（41）	低级别组和高级别组5年生存率分别为58%和17%
Brown等^[27]，2010	HE	356	184（51.7）	172（48.3）	低级别组的总体生存率较高
Nakanishi等^[28]，2011	IHC	82	36（43.9）	46（56.1）	低级别组的无病生存期长于高级别组
Teramoto等^[29]，2013	HE	79	50（63.3）	29（36.7）	低级别组和高级别组三年生存率分别为94.5%和48.8%
Thies等^[30]，2016	IHC，HE	肿瘤内出芽：200	100（50）	100（50）	高级别组和较差pT分期，淋巴结转移和血管浸润相关（P<0.001）
Jesinghaus等^[31]，2017	HE	135	64（47.4）	42（31.1）	高级别组和较小的细胞巢和不良预后相关（P<0.001）

作者，参考文献号，时间	观察方法	病例数	TB低级别（%）	TB高级别（%）	研究结果
Roh等^[24]，2004	HE	56	22（39.3）	34（60.7）	低级别组和高级别组3年生存率分别为72.3%和32.7%
Koike等^[25]，2008	HE	136	54（39.7）	82（60.3）	低级别组的3年和5年生存率分别为92.0%和81.3%，高级别组的3年和5年生存率分别为42.6%和35.4%
Miyata等^[26]，2009	HE	71	42（59）	29（41）	低级别组和高级别组5年生存率分别为58%和17%
Brown等^[27]，2010	HE	356	184（51.7）	172（48.3）	低级别组的总体生存率较高
Nakanishi等^[28]，2011	IHC	82	36（43.9）	46（56.1）	低级别组的无病生存期长于高级别组
Teramoto等^[29]，2013	HE	79	50（63.3）	29（36.7）	低级别组和高级别组三年生存率分别为94.5%和48.8%
Thies等^[30]，2016	IHC，HE	肿瘤内出芽：200	100（50）	100（50）	高级别组和较差pT分期，淋巴结转移和血管浸润相关（P<0.001）
Jesinghaus等^[31]，2017	HE	135	64（47.4）	42（31.1）	高级别组和较小的细胞巢和不良预后相关（P<0.001）

[1]	Siping Zhang, Wei Liu, Pengcheng Ma. Therapeutic effects of lower extremity mild varus alignment after total knee arthroplasty [J]. Chinese Journal of Joint Surgery(Electronic Edition), 2023, 17(06): 808-817.
[2]	Qian Yang, Cuifang Li, Wanqiu Zhang. Analysis of short-term and long-term prognosis and influencing factors of primary liver cancer with spontaneous ruptured hemorrhage after emergency TACE surgery [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 33-36.
[3]	Yansong Li, Huimin Feng, Mingchao Liu, Zepeng Liu, Qiuxia Jiang. Expression and clinical significance of STIP1 in triple negative breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 52-56.
[4]	Zhenjian Jiang, Ming Jiang, Dali Huang. The expression and prognostic value of TK1 and Ki67 proteins in differentiated thyroid carcinoma [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 623-626.
[5]	Qingyan Yan, Xiaomei Yong, Hong Luo, Min Du. Prognostic factors and survival analysis of multicenter elderly patients with metastatic breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 636-638.
[6]	Xin Lu, Jiayi Xu, Yang Liu, Qin Yang, Wenwen Ju, Yinglong Xu. Comparison of the effects of early LC and PTCD continuous LC on liver function and prognosis of patients with acute cholecystitis [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 648-650.
[7]	Bing Pan, Shaocheng Lyu, Xin Zhao, Lixin Li, Ren Lang, Qiang He. Effect of number of dissected lymph nodes on efficacy of pancreaticoduodenectomy for distal cholangiocarcinoma [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 608-612.
[8]	Qikun Zhang, Fuchao Shang, Qi Li, Guangming Li, Menglong Wang. Survival benefit of combined splenectomy in patients with liver cancer complicated with portal hypertension after radical resection [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 613-618.
[9]	Wenhua Zhang, Cui Tao, Tiansong Hu. Clinicopathological characteristics of pedunculated hepatocellular carcinoma in different sites and its effects on postoperative intrahepatic recurrence and prognosis [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 651-655.
[10]	Weizhi Zhang, Lianxin Liu. Expression and significance of IPO7 in hepatocellular carcinoma based on bioinformatics analysis [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 694-701.
[11]	Wentao Ye, Zhongjun Wu, Rui Liao. Relationship between ALOX15 expression in adjacent tissues and prognosis of hepatocellular carcinoma patients after radical resection [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 708-712.
[12]	Yanjun Lu, Jian Ma, Pengyu Bai, Linghong Guo, Haiyi Liu, Bo Jiang, Wenqi Bai, Yixun Zhang. Clinical effect of Nano-carbon on 253 groups of lymph node dissection in laparoscopic radical resection of rectal cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(06): 473-477.
[13]	Yongsheng Li, Jiahe Sun, Shuwei Guo, Yikang Lu, Hongzhou Liu. Short-term postoperative complications and their influencing factors in elderly patients with colorectal cancer [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(9): 962-967.
[14]	Jun Wang, Kunpeng Liu, Lan Yao, Hua Zhang, Yue Wei, Libin Suo, Jun Chen, chengli Miao, Chenghua Luo. Retrospective analysis of anesthesia management of massive transfusion patients undergoing retroperitoneal tumor resection [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(08): 844-849.
[15]	Libin Suo, Kunpeng Liu, Lan Yao, Hua Zhang, Yue Wei, Jun Wang, Jun Chen, Chengli Miao, Chenghua Luo. Key points of anesthesia management and prognostic factors in patients undergoing primary retroperitoneal paraganglioma resection [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(07): 771-776.

Please choose a citation manager

Content to export